QUIZ: Mortality Risk and Screening Criteria
January 2, 2020
In our lung cancer quiz, you'll get a chance to test your knowledge of the mortality risk among patients with lung cancer, and learn more about screening criteria to try reduce these rates.
Bryant Furlow
Quiz: Managing Relapsed/Refractory Multiple Myeloma
December 16, 2019
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to treating patients with relapsed/refractory multiple myeloma
Quiz: Shared Decision-Making in Multiple Myeloma Treatment
November 13, 2019
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.
Quiz: Management of Sarcopenia in Lung Cancer
November 12, 2019
In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer.
Do Higher Testosterone and Folate Deficiency Conspire to Increase Breast Cancer Risk?
October 28, 2019
High testosterone and low folate intake together may drastically increase risk of breast cancer.
Researchers Call for Oncologists to Prescribe Physical Exercise for Breast, Other Cancers
October 21, 2019
New guidelines for exercise for patients with cancer have been released.
All Women with Breast Cancer Should Undergo Multigene Testing, Study Suggests
October 14, 2019
Multigene testing for all woman diagnosed with breast cancer can be “extremely cost-effective.”
Quiz: The Role of CAR T Cells in Multiple Myeloma
October 14, 2019
How much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
New Study Targets Disparities in Male Breast Cancer Patients
October 8, 2019
A new analysis found overall survival may be worse for some male breast cancer patients.
Apalutamide Survival Benefits Unclear for Castration-Resistant Prostate Cancer
October 3, 2019
Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.
